Search

A retrospective study conducted in India between 2001 and 2021 examined the efficacy of cabergoline in treating giant prolactinoma. The study involved 84 patients, and one patient, a woman, was found to have a lack of efficacy with cabergoline treatment. Despite undergoing surgery and receiving cabergoline, the patient required re-surgery due to persistent tumor size and related symptoms. This suggests that cabergoline may not be effective in treating giant prolactinoma. [Extracted from the article]

This article discusses a case series of three men who developed prolactinoma fibrosis while being treated with cabergoline for prolactinoma. Patient 1, a 51-year-old man, opted for surgical intervention after one month of cabergoline treatment and had an unremarkable transsphenoidal resection of the pituitary tumor. Patient 2, a 30-year-old man, underwent an uncomplicated transsphenoidal pituitary tumor resection after being treated with cabergoline for six months. Patient 3, a 52-year-old man, also underwent surgical resection of the tumor after two months of cabergoline treatment. Prolactinoma fibrosis was present in all three cases, and the occurrence was attributed to cabergoline use. However, all three patients were lost to follow-up after discontinuing cabergoline treatment. [Extracted from the article]

A 26-year-old man developed prolactinoma while being treated with testosterone enanthate and testosterone undecanoate for Kallmann syndrome. The man had been diagnosed with Kallmann syndrome at 15 years old and had been receiving hormonal replacement treatment with testosterone enanthate. Later, the treatment was switched to testosterone undecanoate. At 26 years old, he presented with a mild headache and an MRI revealed two pituitary adenomas. He was treated with cabergoline and showed a complete biochemical response. However, hypogonadism persisted despite normal prolactin levels, so testosterone undecanoate was resumed. He also had mild hypercalcaemia and was diagnosed with familial hypocalciuric hypercalcaemia. The prolactinoma was attributed to the testosterone treatments. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 27-year-old transgender man (female at birth and transitioned to male) developed prolactinoma recurrence during treatment with testosterone-cypionate as female to male transgender hormonal therapy [route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 36-year-old man developed a CSF leak following treatment with cabergoline for prolactinoma [route and dosage not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventAn 86-year-old man developed prolactinoma during treatment with leuprorelin for prostate cancer [route, dosage and duration of treatment to reaction onset not stated]. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 50-year-old male to female transgender patient developed prolactinoma during treatemnt with estrogen for gender affirming hormone therapy. [Extracted from the article]

A 28-year-old woman experienced pituitary apoplexy while being treated with cabergoline for prolactinoma. She initially presented with irregular menses and amenorrhea, along with a supranasal headache and nipple crusting. After four weeks of cabergoline treatment, she developed a severe headache and was diagnosed with pituitary hemorrhage. The woman was hospitalized, underwent neurosurgery, and received conservative management for her condition. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventIn a case series of 6·patients, 2·patients [1·male and 1·female; ages not stated] were described, who exhibited lack of efficacy or treatment failure during treatment with bromocriptine or cabergoline for giant prolactinoma [routes not stated]. [Extracted from the article]

Case 2: An adult male to female transgender patient developed hyperprolactinaemia secondary to prolactinoma following treatment with estradiol, ethinylestradiol/cyproterone and cyproterone as GAHT. At the time of current presentation, the patient's GAHT comprised of topical estradiol patch 50 µg/hr twice weekly and cyproterone [cyproterone acetate] 50mg daily. Eighteen months prior to current presentation, patient had started receiving GAHT with topical estradiol gel, cyproterone [cyproterone acetate] 25mg daily and bioidentical progesterone 100mg daily. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study of transgender patients (searched in pathology databases from 2000-2019), a 71-year-old male to female transgender patient was described, who developed prolactinoma following hormone treatment with estrogen, conjugated estrogens and unspecified hormonal therapy [ I routes not stated; not all dosages stated i ]. The male to female transgender patient received high-dose unspecified hormone therapy followed by orchiectomy 30 years before. Based on the clinical picture, the patient was diagnosed with prolactinoma secondary to hormone therapy [ I durations of treatments to reaction onset and outcome not stated i ]. [Extracted from the article]

The article presents a case study of a 41-year-old woman who developed nausea and vomiting during off-label treatment with oral ropinirole 2 milligrams (mg) (immediate release) for prolactinoma.

The article presents a case study of a 61-year-old female patient who developed direct carotid cavernous fistula secondary to ruptured cavernous carotid aneurysm during treatment with cabergoline for recurrent prolactinoma. Other information about the patient, who was presented to the hospital with sudden headache, vomiting, and dizziness and had prior history of transsphenoidal surgery for prolactinoma resection at the age of 27 years, is presented.

Several case studies are presented of patients, who have developed paradoxical increase in insulin-like growth factor-1 (IGF-1) while receiving cabergoline as treatment for prolactinoma.

The article describes the cases of patients, two men aged 36 and 55 and a 28-year-old woman, who suffered from hyperprolactinaemia and prolactinomas while taking amisulpride for schizophrenia. All the patients had schizophrenia of 9, 26, and 4 years' duration respectively. After the psychotic symptoms of the men had improved, they took monthly monitoring of prolactin levels with 6-monthly sella magnetic resonance imagings (MRIs) to monitor changes in the microadenomas.

The article describes the case of an 11-year-old boy who developed resistance to cabergoline during pediatric giant prolactinoma treatment.

The article presents several cases of cerebrospinal fluid (CSF) rhinorrhoea caused by cabergoline for the treatment of macroprolactinoma. Several patients developed CSF rhinorrhoea after receiving cabergoline for macroprolactinoma. The symptoms associated with CSF rhinorrhoea are mentioned. The dosage and length of administration of cabergoline for each patient is cited.

The article presents a case report about the occurrence of digital vasospasm in a woman during treatment with cabergoline for prolactinoma. The woman developed pain in her right hand after receiving cabergoline twice a week postoperatively due to tumor recurrence. Approximately 5 years after staring cabergoline, the drug was discontinued.

Describes a case report on the side effects of the drug risperisone on a patient with bipolar disorder. Development of prolactinoma in the patient; Duration of drug use; Drug dosage being taken by the patient.

The article presents a case study of a 24-year-old woman who developed a brain and optic chiasmal herniations during treatment with bromocriptine for prolactinoma.

The article presents case studies involving two male-to-female sex transfer patients who developed prolactinoma after treatment with estradiol enantate, estradiol valerate, or ethinylestradiol/cyproterone.

An abstract of the article "Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma" by J. K. Prague and colleagues is presented.

An abstract of the article "Cabergoline treatment in invasive giant prolactinoma," by S. Alsubaie and colleagues is presented.

An abstract of the article "Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma," by B. Demartini and colleagues is presented.

The article presents a case report of a 16-year-old girl who developed immune haemolytic anaemia while receiving cabergoline for prolactinoma.

The article presents a case study of an adolescent girl who developed immune haemolytic anaemia while she was treated with cabergoline for her prolactinoma.

The article presents a case study of a women diagnosed with microprolactinoma who developed recurrent neutropenia after receiving bromocriptine, quinagolide and cabergoline in sequence.

An abstract of the article "Dopamine agonist-induced impulse control disorders in a patient with prolactinoma," by S. Almanzar and colleagues is presented.

The article presents a case study of a 44-year-old woman who developed psychosis while was receiving cabergoline for 3 months to treat a prolactinoma.

The article describes the case of a woman who received risperidone but she developed prolactinoma during treatment.

The article describes the case of a 36-year-old man with pituitary prolactinoma who developed brain and optic chiasmal herniation into the pituitary sella while receiving cabergoline therapy.

The article describes the case of a 33-year-old man with a prolactinoma who experienced psychotic symptoms during treatment with quinagolide.

The article describes the case of a male-to-female transsexual who developed prolactinoma while receiving cross-sex hormone therapy with conjugated estrogens and cyproterone.

The article describes a case of prolactinoma in a 42-year-old male-to-female transgender patient during treatment with estradiol enantate.

The article describes a case of cardiac valvulopathy in a 53-year-old man who was receiving cabergoline for prolactinoma.

The article describes the case of male patient who died after developing resistance to cabergoline while undergoing treatment for invasive giant prolactinoma.

The article describes the case of a 54-year-old woman with multiple endocrine neoplasia type 1 syndrome and a giant prolactinoma who developed cerebrospinal fluid (CSF) leak and pneumoencephalus after doses of cabergoline. Previous growth of a tumor have caused erosion of the ethmoid and sphenoid bones with CSF leaks.

The article describes the case of a man with paranoid schizophrenia who was diagnosed with prolactinoma. The patient had been receiving risperidone therapy for 5 years and he developed headache and vision loss. Risperidone was continued. He received pharmacological, radiation and surgical interventions for the prolactin secreting pituitary macroadenoma. His prolactin levels remained elevated and risperidone was replaced with another therapeutic agent and his prolactin levels returned to near-normal levels.

The article describes the case of a 47-year-old woman with a pituitary prolactinoma condition, who developed pathological gambling during treatment with cabergoline. The patient's intake of cabergoline was stopped when she was diagnosed with pathological gambling and major depression with paranoid delusions. She started treatment with escitalopram that led to improved mood two months later and resolution of her gambling and paranoid delusions.

The article describes a medical case of a 44-year-old woman who was diagnosed with microprolactinoma. She started receiving quinagolide 75 milligram three-times daily and about 4 years later, she experienced accelerated thoughts, impulsiveness, difficulty concentrating and talkativeness. The patient had a family history of bipolar disorder.

The article presents a case report of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome in a 22-year-old woman treated with cabergoline for prolactinoma. It references a study by P.E. Jiménez Caballero published in the January 2007 issue of "Cephalgia." One month after receiving the drug, the patient developed left retro-orbital pain that lasted for less than a minute. Her headaches disappeared and she remained pain-free since the drug was discontinued.

The article presents the case of a 43-year-old man who developed short-lasting unilateral neuralgiform headaches with conjunctival injection and tearing associated with cabergoline for microprolactinoma. The symptoms exhibited by the patient during treatment with cabergoline are cited. Other drugs used to treat the headache attacks are also listed, including acetaminophen and sumatriptan.

Discusses research being done on the side effects of bromocriptine in a patient with prolactinoma. Reference to a study by P. Kaushik and colleagues published in the July to August 2004 issue of "Annals of Pharmacotherapy"; Development of severe dilated cardiomyopathy; Improvement of the patient's clinical condition following the discontinuation of the drug.